Indeed, the scaffold of thiazolidin-4-one (4-oxo-thiazolidine) has garnered significant interest in the medicinal chemistry due to its versatility and diverse biological activities, including potential applications in anti-tuberculosis (anti-TB) drug discovery. Its structural properties enable modifications, facilitating the development of various small molecules with desirable pharmacological properties. The review outlines the various medical uses, (anti-TB properties), of thiazolidin-4-derived compounds over the past two decades, highlighting promising candidates such as 53a, 53b, and 53d, which have demonstrated MICs (0.05-0.2) μg/ml against the strain of M. TB H37Rv, along with compound 108 exhibiting a MIC of 0.36 mM. Additionally, compounds 55b, 56, 54k and 54i have shown full effectiveness against Mycobacterium TB (H37Ra), with MIC (0.031-0.125) μg/ml. Acidomycin has exhibited high activity against MDR and XDR as a various strains. This review also explores SAR of the tested compounds and their potential targets.
No takes yet. Share an insight, caveat, or question.
Mody Albalawi (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: